{Reference Type}: Journal Article
{Title}: S3 Guideline Urticaria. Part 2: Treatment of urticaria - German-language adaptation of the international S3 guideline.
{Author}: Zuberbier T;Altrichter S;Bauer S;Brehler R;Brockow K;Dressler C;Fluhr J;Gaskins M;Hamelmann E;Kühne K;Merk H;Mülleneisen NK;Nast A;Olze H;Ott H;Pleimes M;Ruëff F;Staubach-Renz P;Wedi B;Maurer M;
{Journal}: J Dtsch Dermatol Ges
{Volume}: 21
{Issue}: 2
{Year}: 02 2023
{Factor}: 5.231
{DOI}: 10.1111/ddg.14932
{Abstract}: This publication is the second part of the German-language S3 guideline on urticaria. It covers the management of urticaria and should be used together with Part 1 of the guideline on classification and diagnosis. This publication was prepared according to the criteria of the AWMF on the basis of the international English-language S3 guideline with special consideration of health system conditions in German-speaking countries. Chronic urticaria has a high impact on the quality of life and daily activities of patients. Therefore, if causal factors cannot be eliminated, effective symptomatic treatment is necessary. The recommended first-line treatment is to administer new generation, non-sedating H1 antihistamines. If the standard dose is not sufficiently effective, the dose should be increased up to fourfold. For patients who do not respond to this treatment, the second-line treatment in addition to antihistamines in the treatment algorithm is omalizumab and, if this treatment fails, ciclosporin. Other low-evidence therapeutic agents should only be used if all treatments in the treatment algorithm agreed upon by the guideline group fail. Both the benefit-risk profile and cost should be considered. Corticosteroids are not recommended for long-term treatment due to their inevitable severe side effects.